Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer: A case report

BACKGROUND: The management of metastatic progressive radioiodine-resistant differentiated thyroid cancer remains challenging for clinicians. The availability of tyrosine kinase inhibitors (TKIs), sorafenib and lenvatinib, within the last decade has expanded treatment options; however, these lead to...

Descripción completa

Detalles Bibliográficos
Autores principales: Butt, Muhammad Imran, Khalid Bakhsh, Abdulmohsen Mohammed, Nadri, Quaid Johar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085512/
https://www.ncbi.nlm.nih.gov/pubmed/33959480
http://dx.doi.org/10.5306/wjco.v12.i4.272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085512/
https://www.ncbi.nlm.nih.gov/pubmed/33959480
http://dx.doi.org/10.5306/wjco.v12.i4.272

Ejemplares similares